The Prevalence of Local Immunoglobulin E (IgE) Elevation and Its Effect on Intranasal Capsaicin Therapy in the Non-allergic Rhinitis Population
The Prevalence of Local IgE Elevation and Its Effect on Intranasal Capsaicin Therapy in the Non-allergic Rhinitis Population
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Contact
Study Contact
- Name: Amber Luong, MD
- Phone Number: (713) 500-5410
- Email: Amber.U.Luong@uth.tmc.edu
Study Contact Backup
- Name: Kunal R Shetty, MD
- Phone Number: (713) 486-5000
- Email: Kunal.R.Shetty@uth.tmc.edu
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- The University of Texas Health Science Center at Houston
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Chronic rhinitis
Exclusion Criteria:
- Active smoker
- Anatomic source of nasal symptoms
- Chronic rhinosinusitis or other nasal infection
- History of sinonasal malignancy
- Pregnancy or lactation
- Use of medication affecting nasal function (topical steroids, topical anticholinergics, oral antihistamines) in the previous 4 weeks
- Use or abuse of nasal decongestants.
- Positive skin prick test for allergic rhinitis
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Treatment
|
Intranasal capsaicin, 5 applications each delivering 2 micrograms in each nostril, separated by 1 hour.
The nose will be pre-treated with topical lidocaine 15 minutes before each application
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Runny Nose as Measured by the Visual Analog Scale (VAS) at Baseline
Time Frame: baseline
|
The Visual analog scale is scored from 0-10, with 0 being not a problem and 10 being unbearable.
|
baseline
|
|
Runny Nose as Measured by the Visual Analog Scale (VAS) at 4 Weeks Post Treatment
Time Frame: 4 weeks post treatment
|
The Visual analog scale is scored from 0-10, with 0 being not a problem and 10 being unbearable.
|
4 weeks post treatment
|
|
Runny Nose as Measured by the Visual Analog Scale (VAS) at 12 Weeks Post Treatment
Time Frame: 12 weeks post treatment
|
The Visual analog scale is scored from 0-10, with 0 being not a problem and 10 being unbearable.
|
12 weeks post treatment
|
|
Nasal Symptoms of Congestion as Measured by the Visual Analog Scale (VAS) at Baseline
Time Frame: baseline
|
The Visual analog scale is scored from 0-10, with 0 being not a problem and 10 being unbearable.
|
baseline
|
|
Nasal Symptoms of Congestion as Measured by the Visual Analog Scale (VAS) at 4 Weeks Post Treatment
Time Frame: 4 weeks post treatment
|
The Visual analog scale is scored from 0-10, with 0 being not a problem and 10 being unbearable.
|
4 weeks post treatment
|
|
Nasal Symptoms of Congestion as Measured by the Visual Analog Scale (VAS) at 12 Weeks Post Treatment
Time Frame: 12 weeks post treatment
|
The Visual analog scale is scored from 0-10, with 0 being not a problem and 10 being unbearable.
|
12 weeks post treatment
|
|
Nasal Itching as Measured by the Visual Analog Scale (VAS at Baseline
Time Frame: baseline
|
The Visual analog scale is scored from 0-10, with 0 being not a problem and 10 being unbearable.
|
baseline
|
|
Nasal Itching as Measured by the Visual Analog Scale (VAS) at 4 Weeks Post Treatment
Time Frame: 4 weeks post treatment
|
The Visual analog scale is scored from 0-10, with 0 being not a problem and 10 being unbearable.
|
4 weeks post treatment
|
|
Nasal Itching as Measured by the Visual Analog Scale (VAS) at 12 Weeks Post Treatment
Time Frame: 12 weeks post treatment
|
The Visual analog scale is scored from 0-10, with 0 being not a problem and 10 being unbearable.
|
12 weeks post treatment
|
|
Nasal Sneezing as Measured by the Visual Analog Scale (VAS) at Baseline
Time Frame: baseline
|
The Visual analog scale is scored from 0-10, with 0 being not a problem and 10 being unbearable.
|
baseline
|
|
Nasal Sneezing as Measured by the Visual Analog Scale (VAS) at 4 Weeks Post Treatment
Time Frame: 4 weeks post treatment
|
The Visual analog scale is scored from 0-10, with 0 being not a problem and 10 being unbearable.
|
4 weeks post treatment
|
|
Nasal Sneezing as Measured by the Visual Analog Scale (VAS) at 12 Weeks Post Treatment
Time Frame: 12 weeks post treatment
|
The Visual analog scale is scored from 0-10, with 0 being not a problem and 10 being unbearable.
|
12 weeks post treatment
|
|
Change in Maximum Optical Density Determined Via Optical Rhinometry
Time Frame: baseline, immediately post first treatment on Day 1
|
Optical rhinometry provides continuous measurement of blood flow in nasal vessels (via optical density measurements), which serves as an indirect assessment of nasal congestion.
A greater decrease in optical density (OD) from baseline indicates less nasal blood flow and decreased congestion relative to baseline.
|
baseline, immediately post first treatment on Day 1
|
|
Total Nasal Symptom Score as Measured by the Visual Analog Scale (VAS) at Baseline
Time Frame: baseline
|
Total Nasal Symptom score is measured as the sum of four symptom scores for runny nose, nasal symptoms of congestion, nasal itching and sneezing.
Each symptom is scored from 0-10, with 0 being not a problem and 10 being unbearable.
The Total nasal symptom score ranges from 0 - 40, the lower the score the better the outcome.
|
baseline
|
|
Total Nasal Symptom Score as Measured by the Visual Analog Scale (VAS) at 4 Weeks Post Treatment
Time Frame: 4 weeks post treatment
|
Total Nasal Symptom score is measured as the sum of four symptom scores for runny nose, nasal symptoms of congestion, nasal itching and sneezing.
Each symptom is scored from 0-10, with 0 being not a problem and 10 being unbearable.
The Total nasal symptom score ranges from 0 - 40, the lower the score the better the outcome.
|
4 weeks post treatment
|
|
Total Nasal Symptom Score as Measured by the Visual Analog Scale (VAS) at 12 Weeks Post Treatment
Time Frame: 12 weeks post treatment
|
Total Nasal Symptom score is measured as the sum of four symptom scores for runny nose, nasal symptoms of congestion, nasal itching and sneezing.
Each symptom is scored from 0-10, with 0 being not a problem and 10 being unbearable.
The Total nasal symptom score ranges from 0 - 40, the lower the score the better the outcome.
|
12 weeks post treatment
|
|
Maximum Optical Density Determined Via Optical Rhinometry
Time Frame: 12 weeks post treatment
|
12 weeks post treatment
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Local Immunoglobulin E (IgE) Level
Time Frame: baseline, 12 weeks post treatment
|
The IgE levels will be obtained from the brush biopsy of the inferior turbinates.
Change from baseline in local Immunoglobulin E (IgE) level after 12 weeks post treatment.
Data reported is the 12 weeks post treatment value minus the baseline value.
|
baseline, 12 weeks post treatment
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Kunal R Shetty, MD, The University of Texas Health Science Center, Houston
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Respiratory Tract Infections
- Infections
- RNA Virus Infections
- Virus Diseases
- Respiratory Tract Diseases
- Picornaviridae Infections
- Nose Diseases
- Otorhinolaryngologic Diseases
- Rhinitis
- Common Cold
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Dermatologic Agents
- Anesthetics, Local
- Anesthetics
- Central Nervous System Depressants
- Sensory System Agents
- Anti-Arrhythmia Agents
- Voltage-Gated Sodium Channel Blockers
- Sodium Channel Blockers
- Membrane Transport Modulators
- Antipruritics
- Lidocaine
- Capsaicin
Other Study ID Numbers
Other Study ID Numbers
- HSC-MS-19-0333
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.